Up 28% since October, why are CSL shares attracting regulator scrutiny?

CSL shares have soared 28% since the end of October.

| More on:
Shot of a mature scientists working on a laptop in a lab.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CSL Ltd (ASX: CSL) shares are in the red today.

Shares in the S&P/ASX 200 Index (ASX: XJO) biotech stock closed on Friday trading for $299.79. In morning trade on Monday, shares are swapping hands for $296.90, down 1%.

For some context, the ASX 200 is also down 1% at this same time.

Despite that dip, that still sees the stock up 28% since 30 October.

And it makes CSL the third largest company listed on the ASX, with a market cap just shy of $145 billion.

But it's not the big surge in CSL shares that's brought the biotechnology giant under regulatory scrutiny in the United Kingdom. Or, at least, not directly.

What's happening with CSL shares in the UK?

As you may be aware, CSL's three operating segments are CSL Behring, CSL Vifor, and its Seqirus businesses.

CSL Vifor is a global leader in iron deficiency and iron deficiency anaemia therapies. The company acquired Vifor Pharma for US$11.7 billion in 2022 in a deal that boosted CSL shares once completed.

At its capital markets day presentation in October management noted, "CSL Vifor will continue to grow its leading iron franchise through market expansion and life cycle management."

CSL's iron-deficiency treatment is known as Ferinject.

But in possible headwinds for CSL shares, Vifor has run into a potentially sticky patch in the UK, where some four million people suffer from iron deficiency anaemia.

As Reuters reports, the UK's Competition and Markets Authority (CMA) launched an investigation last Wednesday into whether Vifor Pharma disparaged a competing iron-deficiency treatment produced by its competitor Pharmacosmos to benefit Ferinject.

CMA will investigate whether the company impinged on Pharmacosmo's business by making misleading claims to medical professionals about the safety and efficacy of Monofer, Pharmacosmos's competing treatment.

CSL has not yet responded to the allegations.

But if the CMA finds the company did engage in anti-competitive practices, CSL shares could come under pressure amid a potentially sizeable fine and the accompanying reputational damage.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »

Excited couple celebrating success while looking at smartphone.
Healthcare Shares

Guess which ASX 200 stock just jumped 9% on big news

Let's find out what is getting investors excited today.

Read more »